Skip to content

EFFECTS OF RejuvaMatrix ™ ON TELOMERES

THE EFFECTS OF THE RejuvaMatrix ™ ON TELOMERES

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04048044
Enrollment
50
Registered
2019-08-07
Start date
2009-01-31
Completion date
2014-12-31
Last updated
2019-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Telomeres

Brief summary

Lying for 30 to 60 minutes daily in a field of 75 decibels of electromagnetic energy at 54 to 78 GHz will allow telomeres of white blood cells to regenerate

Detailed description

Individuals who are post menopausal and who do not have an implanted electronic device, such as a pacemaker will have base line white blood cell telomeeres measured at Repeat Diagnostics in Vancouver. They will be supplied with a two inch foam mat in the center of which is copper screen with one pound of crushed sapphire. The mat looks like a mattreess and is placed on top of the regular mattress. Participants are provided with a Tesla coil to be attached to a copper wire coming from the copper screen. They will also be provided with a timer so that they can set the Tesla coil to be activated for a maximum of 60 minutes while they sleep. Telomeres will be measured at the end of each year for 5 years.

Interventions

DEVICEExposure to GHz electromagnetic energy (RejuvaMatrix)

75 decibels of 54 to 78 GHz daily for 60 minutes

Sponsors

Holos Institutes of Health, Inc
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

\-

Exclusion criteria

* Implanted electronic device * Major, debilitating disease * Person living with an individual who has an implanted device * Person who is or could become pregnant

Design outcomes

Primary

MeasureTime frame
Length of telomeres after 5 years compared with baseline5 years

Secondary

MeasureTime frame
Total Symptom Index5 years

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026